Sibeprenlimab for treating Immunoglobulin A Nephropathy

Sibeprenlimab is in clinical development for the treatment of adults with Immunoglobulin A Nephropathy (IgAN). IgAN is a chronic kidney disease with a mean age of diagnosis of 42 years in adult patients. In IgAN a protein called immunoglobulin A (IgA) becomes trapped in the very fine filters of the kidney (glomeruli), causing damage and scarring to the kidney. The cause of IgAN is not known, but it is thought that it may be due to over-activity of the immune system. In the early stages, IgA often has no symptoms. The first sign that the patient may notice is blood in the urine. At present, there are no approved treatments for IgAN that do not involve immunosuppression. There is therefore an unmet need to develop new well-tolerated, effective treatment options for IgAN.